The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states
- 31 August 1996
- journal article
- research article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 28 (2) , 235-249
- https://doi.org/10.1016/s0272-6386(96)90307-8
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Effects of Limiting Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with SchizophreniaNew England Journal of Medicine, 1994
- Effect of race on access to recombinant human erythropoietin in long-term hemodialysis patientsPublished by American Medical Association (AMA) ,1994
- Access of Medicaid Recipients to Outpatient CareNew England Journal of Medicine, 1994
- Dismal rehabilitation in geriatric inner-city hemodialysis patientsPublished by American Medical Association (AMA) ,1994
- Early dosing practices and effectiveness of recombinant human erythropoietinKidney International, 1993
- Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approvalPublished by American Medical Association (AMA) ,1992
- Patterns of Care and Expenditures by California Medicaid for Peptic Ulcer and Other Acid-Related DiseasesJournal of Clinical Gastroenterology, 1989
- Payment Restrictions for Prescription Drugs under MedicaidNew England Journal of Medicine, 1987
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987
- Some Interim Results from a Controlled Trial of Cost Sharing in Health InsuranceNew England Journal of Medicine, 1981